0 CHECKOUT

Brain Ischemia - Pipeline Review, H2 2015

  • ID: 3500395
  • October 2015
  • 66 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • CohBar Inc.
  • NeuroNascent, Inc.
  • NeurOp, Inc
  • Prolong Pharmaceuticals
  • Sylentis S.A.
  • Vect-Horus S.A.S
  • MORE

Brain Ischemia - Pipeline Review, H2 2015

Summary

The report ‘Brain Ischemia - Pipeline Review, H2 2015’, provides an overview of the Brain Ischemia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Brain Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Ischemia and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • CohBar Inc.
  • NeuroNascent, Inc.
  • NeurOp, Inc
  • Prolong Pharmaceuticals
  • Sylentis S.A.
  • Vect-Horus S.A.S
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Brain Ischemia Overview

Therapeutics Development

Pipeline Products for Brain Ischemia - Overview

Pipeline Products for Brain Ischemia - Comparative Analysis

Brain Ischemia - Therapeutics under Development by Companies

Brain Ischemia - Therapeutics under Investigation by Universities/Institutes

Brain Ischemia - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Brain Ischemia - Products under Development by Companies

Brain Ischemia - Products under Investigation by Universities/Institutes

Brain Ischemia - Companies Involved in Therapeutics Development

CohBar Inc.

Immune Pharmaceuticals Inc.

Lixte Biotechnology Holdings, Inc.

NeuroNascent, Inc.

NeurOp, Inc

Prolong Pharmaceuticals

Spectrum Pharmaceuticals, Inc.

Sylentis S.A.

The International Biotechnology Center (IBC) Generium

Vect-Horus S.A.S

Brain Ischemia - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

AB-002 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Antisense RNAi Oligonucleotide for Cerebral Ischemia and Dementia - Drug Profile

Product Description

Mechanism of Action

R&D Progress

F-573 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

GNR-014 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Humanin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

LAU-0901 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

LB-100 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

LB-102 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

NP-10679 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

phycocyanobilin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Sanguinate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules for Brain Ischemia - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Antagonize Gpr17 for Brain Ischemia - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SPI-1620 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Stem Cell Therapy for Ischemia - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Synthetic Peptide for Central Nervous System Disorders - Drug Profile

Product Description

Mechanism of Action

R&D Progress

VHN-439 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Brain Ischemia - Recent Pipeline Updates

Brain Ischemia - Dormant Projects

Brain Ischemia - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Brain Ischemia, H2 2015

Number of Products under Development for Brain Ischemia - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Investigation by Universities/Institutes, H2 2015

Brain Ischemia - Pipeline by CohBar Inc., H2 2015

Brain Ischemia - Pipeline by Immune Pharmaceuticals Inc., H2 2015

Brain Ischemia - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2015

Brain Ischemia - Pipeline by NeuroNascent, Inc., H2 2015

Brain Ischemia - Pipeline by NeurOp, Inc, H2 2015

Brain Ischemia - Pipeline by Prolong Pharmaceuticals, H2 2015

Brain Ischemia - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015

Brain Ischemia - Pipeline by Sylentis S.A., H2 2015

Brain Ischemia - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2015

Brain Ischemia - Pipeline by Vect-Horus S.A.S , H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Brain Ischemia Therapeutics - Recent Pipeline Updates, H2 2015

Brain Ischemia - Dormant Projects, H2 2015

Brain Ischemia - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Brain Ischemia, H2 2015

Number of Products under Development for Brain Ischemia - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

CohBar Inc.
Immune Pharmaceuticals Inc.
Lixte Biotechnology Holdings, Inc.
NeuroNascent, Inc.
NeurOp, Inc
Prolong Pharmaceuticals
Spectrum Pharmaceuticals, Inc.
Sylentis S.A.
The International Biotechnology Center (IBC) Generium
Vect-Horus S.A.S

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Cache

Our Clients

  • Cytori Therapeutics, Inc.
  • Pfizer Inc.
  • Medtronic, Inc.
  • St. Jude Medical, Inc.
  • Novo Nordisk A/S
  • Lumedx